Skip to main content
Signal8
Launch Terminal

Genprex, Inc. (GNPX)

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Genprex, Inc. logo

Genprex, Inc.

NASDAQ:GNPXHealthcare
+9.80%$2.24
AH$2.30+2.68%vs close
Mkt Cap$1.84M
Float817K
O/S820K
Vol
$ Vol
RVOL
Inst Own1.7%
SI15.3%
Earnings
Dilution
Genprex, Inc. logoNASDAQ:GNPX$2.24+9.80%
Pipeline4 lead-sponsored trials·2 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 1/2
    Terminated

    TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

    DOTAP:Chol-TUSC2, Erlotinib

    Lung Cancer

    Enrollment
    25
    Start
    Feb 2014
    Primary Completion
    Oct 2016
    Completion
    Sep 2020
    NCT01455389
  • Phase 1/2
    Recruiting

    Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

    quaratusugene ozeplasmid, osimertinib

    Carcinoma, Non-Small Cell Lung

    Enrollment
    158
    Start
    Sep 2021
    Primary Completion
    Mar 2028est.
    Completion
    Mar 2029est.
    NCT04486833
  • Phase 1/2
    Recruiting

    Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

    quaratusugene ozeplasmid, atezolizumab

    Small Cell Lung Cancer Extensive Stage

    Enrollment
    62
    Start
    May 2024
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT05703971
  • Phase 1
    Terminated

    Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

    quaratusugene ozeplasmid, pembrolizumab

    Non Small Cell Lung Cancer

    Enrollment
    5
    Start
    Mar 2022
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT05062980
Search ClinicalTrials.gov for “Genprex”